Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Carr

Gynecology Raleigh, NC Medical Doctor

NPI 1316918238 CMS profile 105226

10931 Raven Ridge Rd #113, Raleigh, NC 27614

Open in the dashboard

General payments

$2,721

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Carr of Raleigh, NC is reported in the CMS Open Payments database as having received $2,721 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $305 14
2024 General $355 18
2023 General $514 27
2022 General $605 51
2021 General $720 39
2020 General $160 9
2019 General $62 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Carr
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to James Carr were reported at $305. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year James Carr Gynecology median Middle half National median
2019 $62 $199 $66–$472 $163
2020 $160 $114 $42–$287 $114
2021 $720 $141 $42–$430 $132
2022 $605 $173 $52–$532 $149
2023 $514 $170 $57–$501 $160
2024 $355 $157 $50–$424 $164
2025 $305 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $749 42 payments
  2. AbbVie, Inc. $409 22 payments
  3. ASCEND Therapeutics US, LLC $206 26 payments
  4. Mayne Pharma Inc. $163 10 payments
  5. Astellas Pharma US Inc $150 7 payments
  6. Lilly USA, LLC $150 8 payments
  7. Pfizer Inc. $144 9 payments
  8. Currax Pharmaceuticals LLC $137 9 payments
  9. Axonics Modulation Technologies, Inc. $109 1 payment
  10. Myovant Sciences Inc. $84 5 payments
  11. Other $421 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,691 144 payments
  2. Gift $17 17 payments
  3. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. Wegovy $509 28 payments
  2. ESTROGEL $206 26 payments
  3. Saxenda $149 12 payments
  4. PREMARIN $148 10 payments
  5. CONTRAVE $137 9 payments
  6. QULIPTA $132 7 payments
  7. Ozempic $130 4 payments
  8. LO LOESTRIN FE $129 7 payments
  9. ZEPBOUND $121 6 payments
  10. UBRELVY $109 6 payments
  11. Other $1,497 79 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record